

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Ladha, Abdullah

eRA COMMONS USER NAME (credential, e.g., agency login):

POSITION TITLE: Assistant Professor

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	END DATE MM/YYYY	FIELD OF STUDY
Aga Khan University , Karachi	MBBS	11/2007	Medicine
University of Minnesota School of Public Health , Minneapolis, MN	MPH	11/2021	Public Health
Hennepin County Medical Center , Minneapolis, MN	Other training	06/2010	Internship (Medicine)
Hennepin County Medical Center , Minneapolis, MN	Resident	06/2012	Medicine
Mayo Clinic , Rochester, MN	Fellow	06/2013	Hospice and Palliative Care
SUNY Upstate Medical University, Syracuse, NY	Fellow	06/2019	Hematology Oncology
Stanford University , Palo Alto , CA	Fellow	06/2020	Blood/Marrow Transplant and Cellular Therapy

**A. Personal Statement**

My area of interest include acute leukemia, specifically acute lymphoblastic leukemia and allogeneic stem cell transplant. I hope to focus on outcome-based research and geriatric oncological issues. During training, my mentors helped me to investigate toxicities related to novel agents used in leukemia like Gemtuzumab and Inotuzumab. After joining hematology department at University of Southern California as Assistant Professor, my team was able to research outcomes of modified USC ALL regimen in B-cell acute lymphoblastic leukemia patients. Our team also researched outcomes in Hispanic patients compared to non-Hispanic patients. We showed use of novel agents in leukemia has potential to reduce disparity in faced by Hispanic leukemia patients. Our team presented these data in recent American Society of Hematology annual meeting. Currently I am formulating a study to use geriatric assessment tools for hematology clinics to assess frailty. In the future I want to focus on population-based studies and investigate barriers to improving outcomes in leukemia patients.

**B. Positions, Scientific Appointments and Honors****Positions and Scientific Appointments**

2022 - Member, American Society of Transplantation and Cellular Therapy (ASTCT)  
 2022 - Co-Chair IGCC (goals of care) workgroup , Norris Cancer Center  
 2020 - Assistant Professor , University of Southern California , Los Angeles , CA  
 2016 - Member , American Society of Hematology  
 2015 - 2016 Clinical Instructor , Mayo Clinic , Rochester , MN

**C. Contribution to Science**

1. During blood and marrow transplant fellowship, my mentors and team helped me to investigate role of novel agents in treatment of acute leukemia and optimizing stem cell collection prior to autologous

## stem cell transplantation

- a. Johnsrud A, Ladha A, Muffy L, Shiraz P, Goldstein G, Osgood V, Shizuru JA, Johnston L, Arai S, Weng WK, Lowsky R, Rezvani AR, Meyer EH, Frank MJ, Negrin RS, Miklos DB, Sidana S. Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. *Transplant Cell Ther.* 2021 Jul;27(7):590.e1-590.e8. PubMed Central PMCID: PMC8378276.
  - b. Ladha A, Hui G, Cheung E, Berube C, Coutre SE, Gotlib J, Liedtke M, Zhang TY, Muffy L, Mannis GN. Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML. *Leuk Lymphoma.* 2021 Jun;62(6):1510-1513. PubMed PMID: 33491527.
  - c. Ladha A, Mannis G, Muffy L. Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. *Leuk Lymphoma.* 2021 Feb;62(2):257-263. PubMed PMID: 32988266.
2. During hematology oncology and palliative care training I investigated interesting clinical presentation of multiple myeloma and wrote review pertaining to care of frail patients.
- a. Ladha A, Zhao J, Epner EM, Pu JJ. Mantle cell lymphoma and its management: where are we now?. *Exp Hematol Oncol.* 2019;8:2. PubMed Central PMCID: PMC6354396.
  - b. Ladha A, Fudym Y, Gentile TC. Clinical Resolution of Red Cell Aplasia Associated del 17p Multiple Myeloma, When Treated With Bortezomib and Dexamethasone. *J Hematol.* 2018 Jan;7(1):29-31. PubMed Central PMCID: PMC7155860.
  - c. Ladha A, Sharma S, Batsis JA, Hanson GA, Swetz KM. Care of the frail elder: the nexus of geriatrics and palliative care. *Minn Med.* 2013 Apr;96(4):39-42. PubMed PMID: 23926830.
3. As medical student I studied health seeking behaviors in urban community of Pakistan, investigated use of novel agents in gastrointestinal stromal cell tumor and unique presentation of renal lymphoma.
- a. Ladha A, Khan RS, Malik AA, Khan SF, Khan B, Khan IN, Samiullah, Kayani WT, Saleem S. The health seeking behaviour of elderly population in a poor-urban community of Karachi, Pakistan. *J Pak Med Assoc.* 2009 Feb;59(2):89-92. PubMed PMID: 19260571.
  - b. Ladha A, Shaikh MU. Response of Imatinib Mesylate in patients with gastrointestinal stromal cell tumour. *J Pak Med Assoc.* 2008 Dec;58(12):696-7. PubMed PMID: 19157325.
  - c. Ladha A, Haider G. Primary renal lymphoma. *J Coll Physicians Surg Pak.* 2008 Sep;18(9):584-5. PubMed PMID: 18803901.